Considerations for using potential surrogate endpoints in cancer screening trials

Webb, Alexis B; Berg, Christine D; Castle, Philip E; Crosby, David; Etzioni, Ruth; Kessler, Larry G; Menon, Usha; Parmar, Mahesh; Steele, Robert J C; Sasieni, Peter D

doi:10.1016/s1470-2045(24)00015-9

Cited by 2 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emerging technologies offer transformative potential for early cancer detection, including liquid biopsy, single-cell sequencing, advanced imaging, and AI-driven analytics, enhancing treatment efficacy and patient outcomes or surrogate endpoints [42]. Multi-omics integration is pivotal, combining genomic, transcriptomic, proteomic, and metabolomic data to understand cancer biology, discover biomarkers, and tailor personalized screening and diagnostics.…”

Section: Discussionmentioning

confidence: 99%

Technology and Future of Multi-Cancer Early Detection

Milner,

Lennerz

2024

Life

View full text Add to dashboard Cite

Cancer remains a significant global health challenge due to its high morbidity and mortality rates. Early detection is essential for improving patient outcomes, yet current diagnostic methods lack the sensitivity and specificity needed for identifying early-stage cancers. Here, we explore the potential of multi-omics approaches, which integrate genomic, transcriptomic, proteomic, and metabolomic data, to enhance early cancer detection. We highlight the challenges and benefits of data integration from these diverse sources and discuss successful examples of multi-omics applications in other fields. By leveraging these advanced technologies, multi-omics can significantly improve the sensitivity and specificity of early cancer diagnostics, leading to better patient outcomes and more personalized cancer care. We underscore the transformative potential of multi-omics approaches in revolutionizing early cancer detection and the need for continued research and clinical integration.

show abstract

Section: Discussionmentioning

confidence: 99%

Technology and Future of Multi-Cancer Early Detection

Milner,

Lennerz

2024

Life

View full text Add to dashboard Cite

show abstract

Alternative endpoints to mortality in cancer screening trials

Kumar

2024

Molecular Oncology

View full text Add to dashboard Cite

The reliance on mortality endpoints in cancer screening trials is not always compatible with the need to accelerate progress in outcomes for patient and public benefit. Evaluation of novel cancer screening technologies, such as multi‐cancer early detection (MCED) tests, could be expedited by using alternative metrics that are measurable earlier than mortality. These include endpoints based on cancer stage at diagnosis, such as reduction in late‐stage cancer incidence, and endpoints following cancer diagnosis, such as eligibility for curative therapy. Innovative trial designs with earlier measures that complement cancer mortality are needed to realise the potential benefits of novel screening technologies such as MCEDs more rapidly.

show abstract

Considerations for using potential surrogate endpoints in cancer screening trials

Cited by 2 publications

References 50 publications

Technology and Future of Multi-Cancer Early Detection

Technology and Future of Multi-Cancer Early Detection

Alternative endpoints to mortality in cancer screening trials

Contact Info

Product

Resources

About